Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Natural and Synthesized Anticancer Bioactive Compounds in Drug Discovery, Formulations...
share announcement

Natural and Synthesized Anticancer Bioactive Compounds in Drug Discovery, Formulations and Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 4660

Special Issue Editor

Prof. Dr. Tatjana P. Stanojković

E-Mail Website
Guest Editor
Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia
Interests: bioactive compounds; natural; synthetic; computational modeling studies; gene expression; nanoparticles; drugs delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A number of innovative strategies aimed at targeting malignant abnormalities of tumor cells are in development and have begun to produce important results. The clinical treatment of neoplastic diseases relies on the complementary procedures of surgery, radiation treatment, immunotherapy, and chemotherapy. Therefore, the discovery of natural and synthetic bioactive compounds with strong cytotoxic activity may represent a starting point for the development of several promising preclinical candidates for cancer treatment. Isolation of bioactive compounds, as well as the synthesis and design of compounds based on state-of-the-art tools, computational modeling studies, artificial intelligence, and machine learning techniques, will provide an understanding of disease mechanisms, and progress in cancer drug discovery. On the other hand, targeted drug delivery and the use of colloidal delivery systems such as nanoparticles, liposomes, micelles, and dendritic biopolymers have drawn significant attention. In addition, so far, it has been confirmed that many of the molecular target changes have been shown at the level of gene expression, and thus, that the effects of bioactive compounds may be mediated by the induction or repression of gene expression via direct molecular interaction (signaling pathways, transcription factors) or, most likely, by epigenetic mechanisms.

This Special Issue has the aim of covering current research and current approaches to the design and development of anticancer drugs. We invite authors to submit original and review articles on all aspects of natural and synthesized anticancer bioactive compounds.

Prof. Dr. Tatjana P. Stanojković
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive compounds
  • anticancer drugs
  • natural products
  • drug discovery
  • targeting drugs delivery
  • computational modeling studies
  • gene expression
  • nanoparticles
  • formulations
  • drug development

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2954 KiB  
Article
Synthesis, Characterization, and Biological Evaluation of Tetrahydropyrimidines: Dual-Activity and Mechanism of Action
by Emilija Milović, Nenad Janković, Jelena Petronijević, Nenad Joksimović, Marijana Kosanić, Tatjana Stanojković, Ivana Matić, Nađa Grozdanić, Olivera Klisurić and Srđan Stefanović
Pharmaceutics 2022, 14(10), 2254; https://doi.org/10.3390/pharmaceutics14102254 - 21 Oct 2022
Cited by 5 | Viewed by 1706
Abstract
In this paper, the synthesis, characterization, and biological evaluation of the novel tetrahydropyrimidines—THPMs are described. THPMs are well-known for wide pharmacological activities such as antimicrobial, anticancer, antiviral, etc. This research includes obtained results of in vitro antimicrobial, anticancer, and α-glucosidase inhibitory activities of [...] Read more.
In this paper, the synthesis, characterization, and biological evaluation of the novel tetrahydropyrimidines—THPMs are described. THPMs are well-known for wide pharmacological activities such as antimicrobial, anticancer, antiviral, etc. This research includes obtained results of in vitro antimicrobial, anticancer, and α-glucosidase inhibitory activities of the eleven novel THPMs. An antibiotic assessment was done against five bacteria (two Gram-positive and three Gram-negative) and five fungi by determining the minimal inhibitory concentration (MIC), using the broth tube dilution method. The most active antibacterial compounds were 4a, 4b, and 4d, while the best antifungal activity was shown by 4e, 4f, and 4k. The lowest MIC value (0.20 mg/mL) was measured for 4e, 4f, and 4k against the Trichophyton mentagrophytes. Moreover, examining the α-glucosidase inhibitory activity revealed the compound 4g as the one with the best activity. The cytotoxic activity was performed on the tumor cell lines (HeLa, K562, and MDA-MB-231) and normal cells (MRC-5). The best antitumor activity was shown by compounds 4b and 4k against HeLa cell lines. The influence on cell cycle and mechanism of action of the most active compounds were examined too. Compound 4b had good antibacterial and anticancer activities, while 4k showed promising antifungal and anticancer activities. Full article
(This article belongs to the Special Issue Natural and Synthesized Anticancer Bioactive Compounds in Drug Discovery, Formulations and Delivery)
►▼ Show Figures

Figure 1

17 pages, 8359 KiB  
Article
Molecular Mechanisms of Cassia fistula against Epithelial Ovarian Cancer Using Network Pharmacology and Molecular Docking Approaches
by Aqsa Kanwal, Farrukh Azeem, Habibullah Nadeem, Usman Ali Ashfaq, Rana Muhammad Aadil, A. K. M. Humayun Kober, Muhammad Shahid Riaz Rajoka and Ijaz Rasul
Pharmaceutics 2022, 14(9), 1970; https://doi.org/10.3390/pharmaceutics14091970 - 19 Sep 2022
Cited by 2 | Viewed by 2406
Abstract
Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. Cassia fistula is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The [...] Read more.
Epithelial ovarian cancer (EOC) is one of the deadliest reproductive tract malignancies that form on the external tissue covering of an ovary. Cassia fistula is popular for its anti-inflammatory and anticarcinogenic properties in conventional medications. Nevertheless, its molecular mechanisms are still unclear. The current study evaluated the potential of C. fistula for the treatment of EOC using network pharmacology approach integrated with molecular docking. Eight active constituents of C. fistula were obtained from two independent databases and the literature, and their targets were retrieved from the SwissTargetPrediction. In total, 1077 EOC associated genes were retrieved from DisGeNET and GeneCardsSuite databases, and 800 potential targets of eight active constituents of C. fistula were mapped to the 1077 EOC targets and intersected targets from two databases. Ultimately, 98 potential targets were found from C. fistula for EOC. Finally, the protein–protein interaction network (PPI) topological interpretation revealed AKT1, CTNNB1, ESR1, and CASP3 as key targets. This is the first time four genes have been found against EOC from C. fistula. The major enriched pathways of these candidate genes were established by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) investigations. To confirm the network pharmacology findings, the molecular docking approach demonstrated that active molecules have higher affinity for binding to putative targets for EOC suppression. More pharmacological and clinical research is required for the development of a drug to treat EOC. Full article
(This article belongs to the Special Issue Natural and Synthesized Anticancer Bioactive Compounds in Drug Discovery, Formulations and Delivery)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop